Perspective Therapeutics Inc (CATX) — Institutional Investor Activity (Q2 2026)

CATX ranks #3977 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

132 institutions disclose a position in CATX, but none treat it as a major bet — even Avidity Partners Management LP, its most concentrated holder, allocates just 3.4% of its own portfolio to it.

BlackRock has added to its CATX position for two straight quarters, increasing it by $19.8M to reach $32.4M today.

UBS Group AG has trimmed its CATX position for two straight quarters, cutting it by $1.0M while still holding $1.5M.

CATX is down 0% today, but institutions show net buying of $58.8M this quarter — a divergence between today's price move and the underlying institutional flow.

CATX reported a net loss of $116.4M over the trailing twelve months.

• Not yet profitable — net loss of $116.4M over the trailing twelve months
• Revenue declined 19.0% year over year
• Net income declined year over year, from -$95.0M to -$116.4M
• Operating cash flow was negative, using $82.5M in cash
• Current ratio of 5.17x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.29x equity — within a conventional range